Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL1872
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NAL1872 is a liposomal formulation of the anthracycline chemotherapy agent doxorubicin, currently in preclinical development by NAL Pharmaceutical Group. As a liposomal injection, it is designed to optimize the pharmacokinetic profile of doxorubicin, potentially enhancing tumor delivery while reducing systemic toxicities, such as cardiotoxicity, that are commonly associated with conventional doxorubicin formulations. The active ingredient, doxorubicin, acts by intercalating between DNA base pairs and inhibiting the enzyme topoisomerase II, which prevents DNA ligation and leads to the induction of apoptosis in rapidly dividing cancer cells. NAL1872 is being investigated for applications in oncology and supportive oncology.
- Other names
- Doxorubicin LiposomeDoxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on NAL1872.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL1872.